ZIRGAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZIRGAN (ZIRGAN).
Ganciclovir is a synthetic guanine derivative that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) and by incorporating into viral DNA, causing chain termination. Ganciclovir is phosphorylated to ganciclovir triphosphate by viral thymidine kinase (UL97) in CMV-infected cells.
| Metabolism | Ganciclovir is not significantly metabolized; it is eliminated primarily by renal excretion via glomerular filtration and active tubular secretion. |
| Excretion | Primarily renal excretion as unchanged drug via glomerular filtration and tubular secretion; >90% of a systemically absorbed dose is recovered unchanged in urine. |
| Half-life | Terminal elimination half-life in patients with normal renal function is approximately 3-4 hours; in renal impairment, half-life may be prolonged up to 30 hours, requiring dose adjustment. |
| Protein binding | <1% bound to plasma proteins. |
| Volume of Distribution | 0.2-0.3 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Not applicable for topical ophthalmic route; systemic bioavailability is negligible (<0.1%). |
| Onset of Action | Not applicable for topical ophthalmic administration; systemic absorption is minimal and no clinical onset data is relevant. |
| Duration of Action | Therapeutic effect duration corresponds to dosing interval (5 times daily); no prolonged duration due to rapid elimination. |
| Molecular Weight | 255.23 |
Instill 1 drop (approximately 0.05 mL) into affected eye(s) 5 times daily (approximately every 3 hours while awake) until corneal ulcer heals, then reduce to 1 drop 3 times daily for 7 days.
| Dosage form | GEL |
| Renal impairment | No systemic absorption anticipated; no dosage adjustment required for renal impairment. |
| Liver impairment | No systemic absorption anticipated; no dosage adjustment required for hepatic impairment based on Child-Pugh classification. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; no specific weight-based dosing guidelines available. |
| Geriatric use | No specific dosage adjustment recommended; use same dosing as adults, with monitoring for tolerability. |
| 1st trimester | Use only if potential benefit justifies potential risk to fetus. No adequate studies in pregnant women. |
| 2nd trimester | Use only if potential benefit justifies potential risk to fetus. No adequate studies in pregnant women. |
| 3rd trimester | Use only if potential benefit justifies potential risk to fetus. No adequate studies in pregnant women. |
Clinical note
Comprehensive clinical and safety monograph for ZIRGAN (ZIRGAN).
| Placental transfer | Systemic absorption is negligible after ophthalmic administration; however, if absorbed, ganciclovir crosses the placenta. |
| Breastfeeding | It is not known whether topical ganciclovir is excreted in human milk. Systemic absorption after ophthalmic use is minimal, but caution should be exercised. |
■ FDA Black Box Warning
Granulocytopenia, anemia, and thrombocytopenia; animal studies have shown carcinogenicity and teratogenicity; rapid infusion may cause increased serum creatinine.
| Serious Effects |
Hypersensitivity to ganciclovir or any component of the formulation
| Precautions | Hematologic toxicity: neutropenia, anemia, thrombocytopenia; renal impairment: dose adjustment required; potential for mutagenicity and carcinogenicity; use in pregnancy only if benefit outweighs risk; may cause fetal harm; monitor renal function and blood counts. |
| Food/Dietary | No clinically significant food interactions are known for ophthalmic ganciclovir. Systemic absorption is minimal, so dietary restrictions are not required. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category C. Animal studies show embryotoxicity and teratogenicity (skeletal abnormalities) at systemic exposures similar to human doses. No adequate human studies. First trimester: potential risk of major malformations; second and third trimesters: risk of fetal toxicity including low birth weight and developmental delay. Use only if benefit outweighs risk. |
| Fetal Monitoring | Monitor intraocular pressure, visual acuity, and slit-lamp examination monthly. Systemic ganciclovir monitoring not required due to minimal absorption. Fetal monitoring via ultrasound if maternal systemic exposure is suspected (e.g., accidental ingestion). |
| Fertility Effects | Animal studies indicate reduced fertility and sperm abnormalities in males (ganciclovir causes testicular toxicity). Females: may cause decreased implantation and increased preimplantation loss. Human data limited; advise contraception during use. |
| Clinical Pearls | Zirgan (ganciclovir ophthalmic gel) is indicated for the treatment of acute herpetic keratitis (dendritic ulcers). Instill one drop five times daily until the corneal ulcer heals, then three times daily for 7 days. Avoid concurrent use of topical steroids during active infection. Monitor for corneal epithelial toxicity; blurred vision may occur transiently after application. |
| Patient Advice | Do not touch the dropper tip to any surface to avoid contamination. · Apply the gel into the affected eye(s) as prescribed, typically 5 times daily. · Wash hands before and after administration. · Temporary blurred vision may occur; avoid driving or operating machinery until vision clears. · Do not wear contact lenses during treatment. · Complete the full course even if symptoms improve. · Report any worsening of symptoms, eye pain, or vision changes to your doctor. |